ESMO 2014 Editor's roundup

vandetanib improves PFS in thyroid cancer

E-hospital: Fully coordinated cancer care and research in Europe

ESMO Highlights: Breast cancer

Research shows chemotherapy has no negative effects on babies in utero

Dabrafenib plus trametinib preferable to vemurafenib alone in melanoma

Nivolumab potentially superior to standard chemo in advanced melanoma

Targeted therapy for iodine-refractory thyroid cancer

Questions raised about the future of lung cancer vaccination?

PD-L1 protein a possible immunotherapy target in mesothelioma

Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma

Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma